Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    France Germany Italy Portugal Spain
  • A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Germany Ireland Spain
  • A study testing tulmimetostat with darolutamide or abiraterone in patients with metastatic hormone-sensitive prostate cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    France Germany Hungary Italy Spain
  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Belgium Croatia Czechia Denmark France Ireland +4
  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Belgium France Ireland Italy The Netherlands Spain
  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Belgium Denmark Finland Norway Sweden
  • Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Austria Belgium Czechia France Germany Greece +5
  • Study on the Effectiveness of Triptorelin, Goserelin Acetate, and Enzalutamide in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Belgium Italy
  • BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    Germany
  • Study of Darolutamide to Increase PSMA Protein Expression in Patients with Hormone Sensitive Prostate Cancer

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    The Netherlands